Cargando…

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies

BACKGROUND: HER2-positive metastatic breast cancer (MBC) relapsing after trastuzumab-based therapy may require continued HER2 receptor inhibition to control the disease and preserve the patients' quality-of-life. Efficacy and safety of lapatinib monotherapy was evaluated in Japanese breast canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toi, M, Iwata, H, Fujiwara, Y, Ito, Y, Nakamura, S, Tokuda, Y, Taguchi, T, Rai, Y, Aogi, K, Arai, T, Watanabe, J, Wakamatsu, T, Katsura, K, Ellis, C E, Gagnon, R C, Allen, K E, Sasaki, Y, Takashima, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778543/ https://www.ncbi.nlm.nih.gov/pubmed/19844234 http://dx.doi.org/10.1038/sj.bjc.6605343

Ejemplares similares

Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study
por: Iwata, Hiroji, et al.
Publicado: (2013)

Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget's Disease to Trastuzumab Monotherapy
por: Wakabayashi, S., et al.
Publicado: (2012)

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer
por: Inoue, Kenichi, et al.
Publicado: (2015)

Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells
por: Ma, S, et al.
Publicado: (2016)

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial
por: Masuda, N., et al.
Publicado: (2018)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
por: Ouyang, D. J, et al.
Publicado: (2021)

A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
por: Ngu, Siew-Fei, et al.
Publicado: (2022)

Increase in the circulating level of hepatocyte growth factor in gastric cancer patients.
por: Taniguchi, T., et al.
Publicado: (1997)

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
por: Kim, S T, et al.
Publicado: (2018)

Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report
por: NOGUCHI, EIICHIRO, et al.
Publicado: (2014)

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck
por: del Campo, J M, et al.
Publicado: (2011)

The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling
por: Hsu, Wan-Tseng, et al.
Publicado: (2018)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
por: Ohno, S., et al.
Publicado: (2013)

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Bartlett, Nancy L., et al.
Publicado: (2023)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

Cavity construction and low power tests of the INS split coaxial RFQ for radioactive nuclei
por: Arai, S, et al.
Publicado: (1995)

Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer
por: Farrugia, M K, et al.
Publicado: (2015)

Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report
por: Guan, Ji-Lin, et al.
Publicado: (2020)

Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer
por: Nakata, B, et al.
Publicado: (2004)

Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response
por: Martin Huertas, Roberto, et al.
Publicado: (2019)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Beam transport design for the linac system in the INS radioactive beam facility
por: Niki, K, et al.
Publicado: (1995)

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study
por: Okada, S, et al.
Publicado: (1999)

Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris
por: Moore, Angela Y., et al.
Publicado: (2022)

Eosinophilic fasciitis preceding relapse of peripheral T-cell lymphoma.
por: Kim, H., et al.
Publicado: (2000)

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
por: Tokunaga, Eriko, et al.
Publicado: (2021)

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
por: Yamazaki, N., et al.
Publicado: (2015)

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020)

First beam tests of the INS split coaxial RFQ for radioactive nuclei
por: Arai, S, et al.
Publicado: (1996)

PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim
por: Park, Sun Hee, et al.
Publicado: (2015)

Characteristics of irradiated silicon microstrip detectors with <100> and <111> substrates
por: Akimoto, T, et al.
Publicado: (2001)

Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain
por: Bhan, Arunoday, et al.
Publicado: (2021)

Patient persistence with first-line antiglaucomatous monotherapy
por: Arias, Alfonso, et al.
Publicado: (2010)

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
por: Powell, C.A., et al.
Publicado: (2022)

Progress report on the construction of the heavy-ion linacs for radioactive nuclei
por: Tomizawa, M, et al.
Publicado: (1995)

Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib
por: Geneste, A., et al.
Publicado: (2020)

(−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo
por: Siddique, Abu Bakar, et al.
Publicado: (2019)

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib
por: Kankia, Ibrahim H., et al.
Publicado: (2017)

Twelve-Year Survival in a Patient With Systemic Sclerosis–Associated Pulmonary Arterial Hypertension on Nifedipine Monotherapy
por: Helgeson, Scott A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5745h62gj2vt7d2klpf1igl36g